STOCK TITAN

Medicus Pharma Announces Closing of $4.25 Million CEO-Led Equity Financings and $10.5 Million Debt Exchange

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Medicus Pharma (MDCX) closed $4.25 million in fixed-price equity financings, including a private placement led by its CEO and other insiders. Approximately $3.0 million came from a registered direct offering; the $1.25 million private placement included $750,000 from the CEO. Both financings were priced at an effective $1.72 per share.

Streeterville Capital exchanged $10.5 million of debt for non-voting, non-convertible preferred shares carrying an 8% cumulative annual dividend payable in kind. The exchange generated no cash. Including approximately $350,000 of additional common-share sales since September 30, 2026, Medicus believes shareholders’ equity exceeds Nasdaq’s $2.5 million continued-listing threshold, subject to Nasdaq confirmation. Financing proceeds are intended to support operations and development, including investigational cancer therapy CD228V, and may also fund debt repayment.

Loading...
Loading translation...
5 points · 2 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 6 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point$4.25 million equity financings closed, providing additional funding for Medicus. 1.1× market cap
  • Major point$10.5 million of Streeterville debt exchanged for preferred shares, reducing outstanding indebtedness. 2.8× market cap
  • Moderate pointApproximately $350,000 raised through additional common-share sales since September 30, 2026. 9.3% of market cap
  • Minor point$1.25 million private placement was led by insiders, including $750,000 from the CEO.
  • Minor point. Forward-looking: it has not happened yet and may not happen.CD228V advancement is among the intended uses of financing proceeds.

Negative

  • Major point97,973 common shares and pre-funded warrants for up to 1,646,213 shares issued at an effective $1.72 per share dilute holders.
  • Major point105,000 preferred shares at $100 each carry an 8% cumulative annual dividend payable in kind.
  • Moderate pointAdditional common-share sales through the at-the-market program also dilute existing holders.
  • Minor point726,730 private-placement common shares issued at $1.72 per share dilute existing holders.
  • Minor pointNasdaq confirmation remains pending for Medicus’ belief that it regained shareholders’ equity compliance.
  • Minor pointDebt exchange generated no cash; indebtedness not exchanged remains outstanding.

News Explained

The closed financing equals 24.5 days of third-quarter 2026 operating cash use at the reported rate.

The closed equity financings issued 97,973 common shares in the registered direct and 726,730 in the private placement, plus pre-funded warrants for up to 1,646,213 shares; the issued shares increase the share count, and warrant exercise could further reduce existing holders’ ownership percentages.

Dr. Bokhari’s reported non-diluted common ownership rose from approximately 3.8% before the transactions to approximately 18.3% after them.

Against reported Q3 2026 operating cash use, the $4.25 million gross financing equals 24.5 days at that rate, while September 30, 2026 cash and equivalents of $5,019,755 equals 29 days.

Sources and calculations
  • Offering gross against the last reported quarterly operating outflow, in days at that rate $4,250,000 / ($15,940,739 / 92) = 24.5 days
  • Available liquidity against the last reported quarterly operating outflow, in days at that rate $5,019,755 / ($15,940,739 / 92) = 29 days

Key Figures

Equity financings: $4.25 million Insider-led private placement: $1.25 million CEO participation: $750,000 +5 more
Equity financings
$4.25 million
Aggregate fixed-price financings, priced at-the-market
Insider-led private placement
$1.25 million
Approximately 30% of total financings
CEO participation
$750,000
Included in the private placement
Debt exchanged
$10.5 million
Streeterville indebtedness exchanged for preferred shares
Preferred shares issued
105,000 shares at $100 per share
Issued in exchange for Streeterville debt
Preferred-share dividend
8% cumulative annual dividend
Payable in kind
Effective share price
$1.72 per share
Registered direct offering and private placement
Nasdaq continued-listing equity threshold
$2.5 million
Company says equity is above the threshold, subject to Nasdaq confirmation

Historical Context

1 past event · Latest: Nov 06
1 event
  1. Nov 06

    Q3 earnings

    24h Move
    +0.8%

    Reported $5.0 million cash and substantial doubt about continuing as a going concern within one year.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

registered direct offering, shelf registration statement, pre-funded warrants, related party transaction, +1 more
5 terms
registered direct offering financial
"Approximately $3.0 million of the financing was conducted via a registered direct offering"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
shelf registration statement financial
"pursuant to the Company’s shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
pre-funded warrants financial
"plus pre-funded warrants to purchase up to 1,646,213 common shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
non-convertible financial
"The preferred shares are non-voting, except as required by law, and non-convertible into common shares."
A non-convertible security is a debt or preferred share that cannot be exchanged for a company’s common stock or another class of shares. For investors this matters because it offers a more predictable stream of income and no upside from equity appreciation—think of it as a fixed lease payment rather than a pie that can grow in size—while also avoiding the risk of dilution to existing shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CEO and other insiders lead private investment of $1.25 million, including $750,000 from the CEO, underscoring confidence in the Company’s precision oncology-led strategy, anchored by its CD228V development program.

PHILADELPHIA, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision-guided, biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the closing of an aggregate of $4.25 million fixed-price equity financings priced at-the-market, including a private placement led by its Chief Executive Officer and other insiders. The private placement totaled $1.25 million, or approximately 30% of the total financings, and was made to a limited number of accredited investors consisting primarily of directors and officers of the Company, including $750,000 from Medicus’ Executive Chairman and Chief Executive Officer. Approximately $3.0 million of the financing was conducted via a registered direct offering pursuant to the Company’s shelf registration statement on Form S-3 and a prospectus supplement. The investment reflects management’s and insiders’ support for the Company’s strategic direction, with CD228V, its investigational antibody-drug conjugate utilizing an established Vedotin platform, at the center of its precision oncology focus.

The Company also announced the exchange of $10.5 million of indebtedness held by Streeterville Capital, LLC (“Streeterville”) for preferred shares. Together with the $4.25 million equity financings, and an additional approximately $350,000 of common shares sold via Medicus’ at-the-market program since September 30, 2026, the Company believes that the transactions have strengthened the Company’s shareholders’ equity above Nasdaq’s $2.5 million continued-listing threshold, and that, subject to Nasdaq confirmation, the Company has regained compliance in respect of Nasdaq rule 5550(b).

Maxim Group LLC acted as financial advisor to the Company in connection with the registered direct offering.

CEO-Led Equity Financing and Strategic Alignment

The $4.25 million fixed-price equity financing priced at-the-market includes $1.25 million of participation led by Company insiders, of which $750,000 is attributable to the CEO. The financing is intended to provide additional working capital to support the Company’s operating and development priorities, including the advancement of CD228V, and may also include the strengthening of the Company’s balance sheet through debt repayment. The Company views this insider participation as a demonstration of alignment with shareholders and conviction in its precision oncology-led direction. The registered direct offering was for 97,973 common shares plus pre-funded warrants to purchase up to 1,646,213 common shares, priced at-the-market at an effective price of $1.72 per share and the private placement was for 726,730 common shares, also priced at-the-market at $1.72 per share. The common shares issued in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and are restricted securities.

Certain directors and senior officers of the Company (collectively, the “Related Parties”) purchased an aggregate of 616,272 common shares pursuant to the private placement (the “Related Party Participation”). Participation by the Related Parties in the private placement was considered a “related party transaction” pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company was exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with the Related Party Participation pursuant to sections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, as neither the fair market value of any securities issued to, nor the consideration paid by, the Related Parties exceeded 25% of the Company’s market capitalization (as defined in MI 61-101). The Company did not file a material change report relating to the Related Party Participation more than 21 days before the expected closing date of the private placement as the details of the Related Party Participation were not settled at such time and the Company wished to close the private placement on an expedited basis for sound business reasons.

Streeterville Debt Exchange and Shareholders’ Equity

Streeterville exchanged $10.5 million of outstanding indebtedness under the Company’s Secured Promissory Notes for 105,000 preferred shares at an issue price of $100 per share. The preferred shares are non-voting, except as required by law, and non-convertible into common shares. They carry an 8% cumulative annual dividend payable in kind and are redeemable at the Company’s option, with no holder redemption right. The exchange did not generate cash proceeds; any indebtedness not exchanged remains outstanding.

Early Warning Disclosure

In connection with the private placement, Dr. Raza Bokhari, company’s Executive Chairman and CEO acquired beneficial ownership of, or control or direction over, an aggregate of 436,046 common shares of the Company indirectly through RBx Capital LP, an entity controlled by Dr. Bokhari.

Prior to the completion of the transactions described herein, Dr. Bokhari had beneficial ownership of, or control or direction over, directly or indirectly, an aggregate of 74,687 common shares of the Company and stock options exercisable within 60 days to acquire an additional 27,500 common shares, representing approximately 3.8% of the issued and outstanding common shares on a non-diluted basis and approximately 5.1% of the issued and outstanding common shares on a partially diluted basis. Following the transactions described herein, Dr. Raza Bokhari has beneficial ownership of, or control or direction over, directly or indirectly, an aggregate of 510,733 common shares of the Company and stock options exercisable within 60 days to acquire an additional 27,500 common shares, representing approximately 18.3% of the issued and outstanding common shares on a non-diluted basis and approximately 19.1% of the issued and outstanding common shares on a partially diluted basis.

Dr. Bokhari acquired the common shares for investment purposes. Dr. Bokhari may seek to increase or decrease his investment, directly or indirectly in the Company through the market, privately or otherwise, depending on market conditions or any other relevant factors, or may in the future develop plans or intentions relating to any of the other actions listed in (a) through (k) of Form 62-103F1 – Required Disclosure Under the Early Warning Requirements.

Dr. Bokhari's business address is 300 Conshohocken State Road, Suite 200, West Conshohocken, PA 19428, United States.

For the purposes of this news release and early warning disclosure, the pro forma number and percentage of outstanding common shares owned and controlled by Dr. Bokhari following completion of the transactions described herein is based on 2,788,106 outstanding common shares following the completion of the private placement and the registered direct offering.

This portion of this news release is being issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues. An early warning report will be filed by Dr. Bokhari on SEDAR+ (www.sedarplus.ca) under the Company's issuer profile. Persons who wish to obtain a copy of the early warning report to be filed by Dr. Bokhari may obtain a copy of such report from SEDAR+ (www.sedarplus.ca) or by contacting Carolyn Bonner, President and CFO of the Company at (610) 636-0184 or cbonner@medicuspharma.com.

For further information contact:

Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com  

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is actively engaged in multiple countries across three continents.

The Company’s current therapeutic assets are:

CD228V ADC, an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform, directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types, such as melanoma, squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer.

SkinJect®, an investigational novel localized immuno-oncology precision product focused on basal cell carcinoma (BCC) lesions in Gorlin Syndrome patients, a rare autosomal dominant disease also called nevoid BCC syndrome.

Teverelix®, an investigational next-generation GnRH antagonist, is being developed as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients, patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate and symptomatic endometriosis.

Medicus’ strategy is to advance select programs through Phase 2 proof-of-concept and key clinical and regulatory inflection points that substantially reduce development risk and increase their attractiveness to potential pharmaceutical partners. By generating decision-grade clinical, regulatory and operational datasets, the Company seeks to create opportunities for strategic collaborations, regional licensing transactions and broader commercialization partnerships with established pharmaceutical companies. As data matures across its programs, Medicus intends to continue building differentiated development packages designed to maximize asset value while maintaining capital efficiency and development focus.

This news release shall not constitute an offer to sell, or a solicitation of an offer to buy, or a recommendation to purchase, any securities in any jurisdiction, nor shall there be any sale, issuance or transfer of any securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful under the laws of such jurisdiction. This news release does not constitute either advice or a recommendation regarding any securities. The common shares issued in the private placement and the preferred shares issued to Streeterville have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking statements” or “forward-looking information” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, “forward-looking statements”). “Forward-looking statements” are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company’s financial performance and business outlook, the equity financing and the debt exchange, including the anticipated use of proceeds, the anticipated accounting treatment of the preferred shares as permanent equity, the Company’s pro forma shareholders’ equity, the Company’s belief that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), any determination by Nasdaq regarding the Company’s compliance, the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements, the development of SkinJect® and the potential benefits thereof for those suffering with Gorlin Syndrome, the planned initiation, timing, design, conduct and results of the SKNJCT-005 registrational study in patients with Gorlin Syndrome, the projected cost of the SkinJect® development program, the Company’s decision to develop SkinJect® exclusively for patients with Gorlin Syndrome, the timing and outcome of the FDA’s review of the Company’s Orphan Drug Designation and Rare Pediatric Disease Designation applications for SkinJect®, the development of Teverelix® and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix® for AURr, cardiovascular high-risk advanced prostate cancer (“APC”), women’s health indications like endometriosis, the FDA’s feedback regarding the Company’s Phase 2b/3 registration-intent protocol for Teverelix® in APC, the proposed design of the Phase 2b/3 registration-intent program, the potential to reduce the overall planned APC clinical development program from approximately 1,500 patients to approximately 600 patients, the establishment of a defined, capital-efficient and partner-ready registrational pathway for Teverelix® without Medicus independently funding an additional APC clinical development study, Medicus’ intent and ability to out-license or otherwise strategically partner the Teverelix® APC program, the anticipated completion of GMP-grade manufacturing, quality-release and other clinical study readiness steps, whether the proposed cardiovascular-focused registrational strategy, including the 12-month non-calcified coronary plaque endpoint assessed using non-invasive coronary CCTA and the evaluation of Teverelix® effects on APC patients at increased cardiovascular risk, could support registration, the Company’s capital-efficient portfolio strategy and the anticipated benefits thereof, the anticipated reduction in the Company’s operating expenses, the Company’s view that SkinJect® and Teverelix® are partner-ready programs, the Company’s co-development and license agreement with Pfizer with respect to CD228V, the Company’s strategy relating thereto and the anticipated benefits thereof, including whether Pfizer elects to fund any development activities for CD228V and whether the parties enter into a definitive agreement in respect thereof, the Company’s ability to identify, negotiate and complete partnerships, licensing, co-development or other strategic transactions and the timing, terms and anticipated benefits thereof, the Company’s plans and expectations relating to the development, manufacture and commercialization of CD228V across human therapeutic indications, including the Company’s intention to focus initial development on melanoma with potential subsequent development in squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and esophageal cancer, the Company’s plans to prioritize clinical proof-of-concept for CD228V in melanoma, including relapsed, refractory or immunotherapy-resistant disease, the potential for CD228V to achieve an objective response rate exceeding 30% in melanoma and to support a future monotherapy registration strategy, the potential for biomarker research to guide development, the potential for evidence generated in melanoma to support evaluation of CD228V in additional CD228-expressing solid tumors, the timing, design, conduct and results of any future clinical study of CD228V, and the potential market opportunities related to CD228V, SkinJect® and Teverelix® and the Company’s other therapeutic assets. Forward-looking statements are often, but not always, identified by the use of such terms as "may", “on track”, “aim”, "might", "will", "will likely result", “could,” “designed,” "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", “goal”, “strive”, “prioritize”, “pursue”, “intended”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2025, as amended, and its quarterly report on Form 10-Q for the quarter ended September 30, 2026, and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Medicus Pharma raise in its CEO-led equity financings?

Medicus closed $4.25 million in fixed-price equity financings at an effective $1.72 per share. Approximately $3.0 million came through a registered direct offering, and $1.25 million through a private placement led by the CEO and other insiders. The CEO contributed $750,000.

What are the terms of Medicus Pharma’s Streeterville debt exchange?

Streeterville exchanged $10.5 million of outstanding indebtedness for 105,000 preferred shares issued at $100 each. The shares are non-convertible and non-voting except as required by law, with an 8% cumulative annual dividend payable in kind. Medicus may redeem them, but Streeterville has no holder redemption right.

How much Medicus Pharma stock does CEO Raza Bokhari own after the financings?

Following the transactions, Raza Bokhari beneficially owns or controls 510,733 common shares, representing approximately 18.3% of outstanding common shares on a non-diluted basis. He also holds options exercisable within 60 days for 27,500 shares, bringing his partially diluted ownership to approximately 19.1%. Before the transactions, his non-diluted ownership was approximately 3.8%.

Keep reading